Flavivirus peptide sequences, epitopes, and methods and uses thereof
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11806393-B2
Publication Date
2023-11-07
Expiration Date
Abstract
The present application relates to composition of matter, processes and use of composition of matter relating to flavivirus peptides and epitopes, for example, for therapeutic or preventative vaccination against a flavivirus, and/or for inducing, enhancing, or sustaining an immune response against a flavivirus, and/or for detecting an infection with or an exposure to a flavivirus in a subject. The flavivirus may be for example the Zika and/or Dengue virus.
Core Innovation
The invention relates to flavivirus peptide/epitope compositions comprising one or more peptides selected from a group of peptides defined by an amino acid sequence set forth in SEQ ID NO: 125 to SEQ ID NO: 129. The compositions include an acceptable carrier or diluent and are used to induce, enhance, or sustain an immune response against Zika virus in a subject.
A central aspect of the invention is the use of these SEQ ID NO: 125 to SEQ ID NO: 129 peptides to stimulate, induce, promote, increase, or enhance T-cell activity against Zika virus. The provided content further connects anti-Zika virus immune outcomes to T-cell responses, including the promotion or elicitation of a CD4+ T cell response.
The invention also addresses treating or reducing susceptibility to Zika virus infection or pathology by administering a composition containing the SEQ ID NO: 125 to SEQ ID NO: 129 peptides. The therapeutic use is associated with reducing or inhibiting Zika virus infection-related measures and associated pathology, including effects on infection-related viral measures and adverse physiological conditions.
Claims Coverage
The independent claims cover administering or contacting a subject with a composition comprising an acceptable carrier or diluent and one or more peptides defined by SEQ ID NO: 125 to SEQ ID NO: 129, to drive anti-Zika virus immune responses, anti-Zika virus T cell activity, and treatment or reduction of susceptibility to Zika virus infection or pathology. Four main inventive feature themes are present.
T cell contacting with SEQ ID-defined Zika peptides
Contacting T cells of the subject with an effective amount of a composition comprising an acceptable carrier or diluent, and one or more peptides selected from the group of a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NO: 125 to SEQ ID NO: 129.
Administering SEQ ID-defined Zika peptides to stimulate immune response
Administering to a subject an effective amount of a composition comprising an acceptable carrier or diluent, and one or more peptides selected from the group of a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NO: 125 to SEQ ID NO: 129.
Treating Zika infection or pathology using SEQ ID-defined peptides
Administering to a subject an amount of a composition comprising an acceptable carrier or diluent, and one or more peptides selected from the group of a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NO: 125 to SEQ ID NO: 129.
Inducing anti-Zika virus T cell activity using SEQ ID-defined peptides
Administering to a subject an amount of a composition comprising an acceptable carrier or diluent, and one or more peptides selected from the group of a peptide consisting of an amino acid sequence set forth in any one of SEQ ID NO: 125 to SEQ ID NO: 129.
Across the independent claims, the claims coverage centers on administering or otherwise contacting a subject with an acceptable carrier/diluent composition containing one or more peptides defined by SEQ ID NO: 125 to SEQ ID NO: 129, to induce, increase, promote, or enhance immune responses and anti-Zika virus activity of T cells, and to treat or reduce susceptibility to Zika virus infection or pathology.
Stated Advantages
Inducing, enhancing, or sustaining an immune response against Zika virus.
Stimulating, inducing, promoting, increasing, or enhancing an immune response against Zika virus.
Inducing, increasing, promoting or stimulating anti-Zika virus activity of T cells.
Treating a subject for a Zika virus infection.
Treating, reducing or inhibiting susceptibility to Zika virus infection or pathology.
Reducing or inhibiting Zika virus titer and/or Zika virus clearance/proliferation measures.
Reducing or inhibiting Zika virus protein and nucleic acid levels and/or synthesis.
Improving adverse physiological conditions, disorders, illness, disease, symptoms, complications, and/or pathology associated with Zika virus infection.
Documented Applications
Vaccination/immune modulation by inducing, enhancing, or sustaining immune responses against Zika virus, including T-cell activity and CD4+ T cell responses.
Therapeutic treatment by treating, reducing or inhibiting susceptibility to Zika virus infection or pathology and by reducing or inhibiting Zika virus infection-related measures and associated adverse conditions.
In vitro/in vivo detection of flavivirus infection or exposure via T-cell response assays.
Interested in licensing this patent?